Sinotau

Sinotau, officially known as Beijing Sinotau International Pharmaceutical Technology Co., Ltd., is an innovative pharmaceutical company based in Beijing, China.

Founded in 2005, Sinotau specializes in the research, development, manufacturing, and marketing of next-generation radiopharmaceuticals. The company focuses on targeted radionuclide theranostics, which integrate diagnostic imaging and targeted radiotherapy to enhance precision medicine. Sinotau offers a comprehensive range of services across the radiopharmaceutical value chain, including early-stage discovery, clinical development, regulatory support, and commercialization. Its product portfolio features targeted radiopharmaceuticals aimed at oncology, neurodegenerative diseases, and cardiovascular disorders. Notable developments include agents for prostate cancer diagnosis and Alzheimer’s disease, with several products at various stages of clinical development. Sinotau has established modern production facilities in multiple regions of China and has secured significant financing to support its innovative initiatives. The company aims to expand its market reach both domestically and internationally through collaborations with global partners.